{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-004117","form_type":"8-K","ticker":"CDNA","cik":"0001217234","company_name":"CareDx, Inc.","filed_at":"2023-01-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:44.098485+00:00","generated_at":"2026-06-20T17:33:02.289905+00:00","sec_items":["2.02","9.01","7.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"CareDx prelim Q4 rev $81.9-82.2M (+4% YoY); FY22 rev ~$321M (+8%); $50M buyback authorized","bullets":["Preliminary Q4 2022 revenue $81.9-82.2M vs $79.2M in Q4 2021; testing services rev $64.9-65.2M (down from $68.6M).","Patient testing volume ~47,700 (+14% YoY), including ~2,300 AlloSure Lung tests.","Authorized $50M share buyback; cash & equivalents ~$292M with no debt.","Patient and digital solutions rev $28.8M in FY22 vs $10.3M in FY21, a 180% increase.","CEO targets adjusted EBITDA profitability in H1 2023; full guidance on Feb 2023 call."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-004117","json":"https://secwatch.observer/filing/0001193125-23-004117.json","markdown":"https://secwatch.observer/filing/0001193125-23-004117.md","text":"https://secwatch.observer/filing/0001193125-23-004117.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1217234/000119312523004117/0001193125-23-004117-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1217234/000119312523004117/d443407d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-20T17:33:02.289905+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"e720157937b406b90184079c8a38aefda453b096","claim":"CareDx, Inc. reported the fourth quarter ended December 31, 2022 results: revenue $81.9 million to $82.2 million.","evidence_excerpt":"Preliminary revenue for the three months ended December 31, 2022, is expected to be between $81.9 million and $82.2 million","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1217234/000119312523004117/0001193125-23-004117-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter ended December 31, 2022"},{"label":"Revenue","value":"$81.9 million to $82.2 million"},{"label":"Result","value":"preliminary results"}],"fact_type":"earnings_release"},{"claim_id":"f15233d2922377f2e9037647942995404e15e25d","claim":"CareDx, Inc. reported the full year ended December 31, 2022 results: revenue $321.3 million to $321.6 million.","evidence_excerpt":"Preliminary revenue for the full year ended December 31, 2022, is expected to be between $321.3 million and $321.6 million","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1217234/000119312523004117/0001193125-23-004117-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the full year ended December 31, 2022"},{"label":"Revenue","value":"$321.3 million to $321.6 million"},{"label":"Result","value":"preliminary results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}